AZ Shows Off osimertinib setting the groundwork for move into 1L EGFRm+ NSCLC AZ´s symposium presentations focused on promoting the value of 3rd Gen TKIs and liquid biopsies. AZ took the opportunity to emphasize that osimertinib is the only 3rd Gen TKI in the market highlighting the discontinuation of rociletinib […]